252.93
過往表現並非未來業績的可靠指標. 所示股價僅供參考，可能與實時市價存在差異。
交易 Axsome Therapeutics Inc - AXSM 差價合約
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer''s disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.最新股票文章
期貨是什麼？一文看懂期貨合約運作、種類與香港交易入門
期貨是什麼？本文拆解期貨合約組成、保證金計算與常見類型（股指、商品、加密貨幣），並詳解香港恒指期貨玩法、開戶流程及風險管理，新手必讀入門教學。
10:57, 16 6月 2026
ETF是什麼？一文讀懂交易所買賣基金的運作、種類與投資方法
ETF是什麼？本文深入解析交易所買賣基金的運作原理、主要類型（指數、債券、主題、槓桿反向）、投資費用及香港/美股熱門ETF清單，幫助新手快速開始ETF投資。
10:21, 16 6月 2026
港人實戰：如何佈局 SpaceX IPO 前後的交易節奏
SpaceX以750億美元完成歷史性IPO，估值1.77萬億美元。深度解析港股CFD交易策略、供應鏈映射與恒生指數聯動，助投資者理解太空經濟相關市場動態。資本面臨風險。
08:58, 16 6月 2026
SpaceX上市首日收漲19%——IPO後如何交易SpaceX SPCX差價合約
SpaceX（SPCX）於2026年6月12日在納斯達克首次上市，開盤報150美元，收盤報160.95美元，較135美元的IPO發行價上漲19.2%。
08:23, 16 6月 2026
Reuters News•Europe
11:36 (UTC), 3 undefined 2026
評級和評論
評級和評論
